Mechanism of Action: AMPA Receptor Antagonists

Drugs with Mechanism of Action: AMPA Receptor Antagonists

Applicant	Tradename	Generic Name	Dosage	NDA	Approval Date	TE	Type	RLD	RS	Patent No.	Patent Expiration	Product	Substance	Delist Req.	Exclusivity Expiration
Teva Pharms Usa Inc	PERAMPANEL	perampanel	TABLET;ORAL	209801-003	May 23, 2025	AB	RX	No	No
Taro	PERAMPANEL	perampanel	TABLET;ORAL	209538-005	Nov 25, 2025	AB	RX	No	No
Teva Pharms Usa Inc	PERAMPANEL	perampanel	TABLET;ORAL	209801-004	May 23, 2025	AB	RX	No	No

AMPA Receptor Antagonists: Market Dynamics and Patent Landscape

Last updated: April 23, 2026

What drugs define the AMPA receptor antagonist landscape today?

AMPA receptor antagonists block ionotropic signaling through the AMPA subtype of glutamate receptors (often including AMPA-triggered excitotoxicity pathways). In drug development and marketed products, the class is anchored by perampanel (a non-competitive AMPA receptor antagonist) and multiple program families attempting to expand beyond epilepsy into CNS pain, neurodegeneration, and other excitatory-dysregulation indications.

Market anchor: perampanel (FYCOMPA)

• Mechanism: Non-competitive AMPA receptor antagonist.
• Commercial positioning: Branded therapy for focal seizures (with or without secondary generalization) and primary generalized tonic-clonic seizures; label expansion varies by region.
• Form factor: Oral tablets (and regional formulations).
• Patent strategy pattern: Perampanel’s IP stack typically uses layered protection: compound patents plus salt/polymorph, formulation, and method-of-use claims (where filed).

Development universe (dominant mechanism target)

Across non-perampanel candidates, the consistent pattern is AMPA antagonism with CNS exposure optimization:

• Oral CNS small molecules targeting non-competitive AMPA receptor sites.
• Derivatives and analogs built around a known pharmacophore.
• Adjunct IP via prodrugs, salt forms, controlled-release or formulation claims, and method-of-treatment.

How does the AMPA antagonist market behave commercially?

Prescription demand is concentrated

Commercial volume for the class is dominated by perampanel because:

• It is the only AMPA antagonist with broad, mature commercialization across major markets.
• Competitors with similar mechanisms face entrenched clinical and payer adoption challenges, especially where efficacy is measured against established antiseizure standards.

Pricing pressure and payer scrutiny are typical CNS-drug drivers

For CNS brands, market dynamics reflect:

• Reimbursement sensitivity to comparative efficacy and tolerability.
• Safety-driven diffusion limits: AMPA antagonists often carry CNS adverse-effect profiles (dizziness, somnolence, balance disorders for perampanel class members), which affect dose titration and persistence.
• Formulary management: seizure therapeutics typically experience step edits and prior authorization in many payers.

Competitive dynamics: class expansion vs. differentiation

The development question is not whether AMPA antagonism works in principle, but whether the entrant can deliver:

• improved tolerability,
• superior exposure-response,
• or an endpoint advantage in a specific seizure or CNS indication.

What is the patent landscape structure for AMPA receptor antagonists?

IP layers that recur across the class

Across AMPA antagonist programs, patents tend to fall into four buckets:

1. Compound (core chemical entity)
   • Claims directed to the antagonist scaffold and specific analogs.
2. Salts, polymorphs, solvates
   • Narrow but enforceable claims that can extend exclusivity.
3. Formulations and dosing regimens
   • Controlled-release or improved bioavailability formulations; method-of-use claims for specific seizure populations or dosing schedules.
4. Method of treatment
   • Medical use claims tied to epilepsy phenotypes and additional CNS indications.

Patent life-cycle effect on market entry timing

For any entrant attempting to compete with perampanel, the risk profile is driven by:

• whether their mechanism claims read across to existing chemical entities,
• whether formulation or method-of-treatment claims are enforceable for the target indication,
• and whether a competitor can carve a non-infringing pathway (new scaffolds, different receptor binding modality, or distinct indication claims).

Where does perampanel sit in the IP timeline?

Perampanel is the key reference point because its IP stack sets the competitive “floor” for AMPA antagonism in epilepsy.

US and EU exclusivity framework (high-level)

• Primary composition patents typically provide the earliest expiration.
• Secondary protection in key jurisdictions can extend market exclusivity through formulation or method-of-use protection.

Commercial consequence

• Until perampanel’s primary and secondary protections expire in a jurisdiction, the competitive set is constrained to:
  • products with licensing arrangements, or
  • distinct compounds where IP does not overlap in enforceable claim scope.

How do patent claims typically map to freedom-to-operate (FTO) risk?

Claim scope that matters in AMPA antagonists

An investor or R&D team evaluating entry into the AMPA antagonist space typically faces three “risk hot spots”:

1. Core scaffold similarity
   • If an entrant’s chemical series falls within the same structural definitions in existing compound claims, it can trigger infringement despite different substitutions.
2. Formulation and salt choices
   • Even when the compound differs, salt/polymorph/formulation claims can capture broad compositions if the entrant adopts an overlapping crystalline form or manufacturing approach.
3. Method-of-use in epilepsy
   • If an entrant targets an indication covered in method-of-treatment claims tied to AMPA antagonists for specific seizure types, the claim-set may overlap.

Practical result

The highest FTO risk usually comes from:

• using a marketed-like dosing and formulation paradigm,
• targeting the same epilepsy phenotypes,
• and landing in a chemical space close to existing reference series.

Which competitors have attempted to challenge perampanel by targeting AMPA?

Non-perampanel AMPA antagonists historically include candidates built around either non-competitive antagonism or related modulation strategies. The class record shows:

• multiple programs reaching clinical evaluation,
• but limited late-stage success versus perampanel’s commercial entrenchment.

The competitive pattern is consistent:

• early compounds enter with AMPA antagonism as the headline,
• differentiation shifts toward tolerability and PK,
• and IP strategy becomes decisive late in development (patent defensibility and market exclusivity).

What filings and patent sources anchor the landscape analysis?

A reliable patent landscape for AMPA antagonists is built from:

• patent family membership (INPADOC style),
• jurisdictional claim sets (US/EPO vs. national rights),
• continuations/divisionals (US-specific),
• and regulatory exclusivity links for dosing form and method-of-use scope.

Landmark reference sources used in this space

• USPTO Patent Center for assignee search and claim language review.
• EPO Espacenet for family clustering and EPO prosecution history.
• FDA Orange Book for US-listed drug patents and exclusivity links (where available for perampanel and any related salt/formulation).
• WIPO PATENTSCOPE for PCT families providing early disclosure and continuation pathways.

What is the business outlook for AMPA receptor antagonists under the current patent regime?

Likely equilibrium: narrow entry windows and targeted differentiation

Given perampanel’s dominance, the market outlook for new entrants is defined by:

• IP clearance feasibility in top markets,
• the ability to create a defensible compound family that does not overlap existing chemical definitions,
• and the ability to claim new indication sub-populations or dosing strategies that reduce method-of-use overlap risk.

Investment implication

Where a program’s IP is weak beyond the core compound, it typically struggles to secure long-lived exclusivity against:

• secondary protection for known scaffolds,
• and aggressive challengers using prior art around known AMPA antagonist series.

Patent and market signals to monitor for decision-making

Technical patent signals

• Broad Markush scope versus narrow substitutions
• Presence of salt/polymorph claims that map to commercially preferred forms
• Method-of-treatment claims that align with reimbursable label language or high-value seizure phenotypes
• Whether US continuations exist that indicate claim expansion

Commercial signals

• Evidence of payer-relevant tolerability improvements (dose reduction, improved persistence)
• Trial endpoints framed against current standards of care rather than broad seizure reduction measures
• Evidence that the entrant can win formularies without requiring extraordinary discounts

---

Key Takeaways

• Perampanel is the commercial anchor for AMPA receptor antagonism in epilepsy, shaping both competitive and IP timing conditions.
• AMPA antagonist IP usually stacks compound claims with secondary protection in salts/polymorphs, formulations, and method-of-treatment, so FTO risk often concentrates in those layers.
• Market entry is constrained by the enforceability of existing perampanel-linked claim sets and by the difficulty of proving non-infringing differentiation in method-of-use and commercial formulation choices.
• Successful entrants tend to combine (1) a defensible chemical scaffold, (2) enforceable secondary protection, and (3) label-aligned differentiation to avoid overlapping method-of-treatment coverage.

FAQs

1. What is the core mechanism shared by AMPA receptor antagonists?
   They block AMPA receptor-mediated glutamatergic signaling, often as non-competitive antagonists, reducing excitatory neurotransmission linked to seizure generation.

2. Why does perampanel dominate commercialization in this class?
   It has mature clinical adoption in epilepsy, entrenched payer and prescriber workflows, and an IP stack that delays or limits direct competition.

3. Which IP layers most often determine AMPA antagonist freedom-to-operate risk?
   Compound scope, salt/polymorph, formulation claims, and method-of-treatment claims tied to seizure phenotypes.

4. What strategy most improves defensibility for a new AMPA antagonist entrant?
   Build around a chemical series with clear non-overlap to existing compound claims, then protect commercially relevant salts/forms and dosing regimens.

5. What market signals predict whether an AMPA antagonist will gain formulary traction?
   Demonstrated tolerability improvements that support dosing persistence, plus trial evidence that translates into payer-relevant comparative efficacy.

---

References

[1] FDA Orange Book. “Drug Products (Orange Book) entries for perampanel and related patents.” U.S. Food and Drug Administration. https://www.accessdata.fda.gov/scripts/cder/ob/
[2] USPTO Patent Center. “Patent search and assignee/family tools for AMPA receptor antagonists (perampanel and related series).” United States Patent and Trademark Office. https://patentscope.wipo.int/
[3] EPO Espacenet. “Patent family data and publication records for AMPA receptor antagonists.” European Patent Office. https://worldwide.espacenet.com/
[4] WIPO PATENTSCOPE. “PCT publication families for AMPA receptor antagonists.” World Intellectual Property Organization. https://patentscope.wipo.int/